Cidara Total Assets from 2010 to 2025

CDTX Stock

USD 22.47 0.63 2.73%

Cidara Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

162.3 M

Current Value

214.8 M

Quarterly Volatility

37.8 M

Yuan Drop

Covid

Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14.7 M or Other Operating Expenses of 186.2 M, as well as many indicators such as Price To Sales Ratio of 141, Dividend Yield of 0.0 or PTB Ratio of 1.1. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.

Check out the analysis of Cidara Therapeutics Correlation against competitors.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Cidara Therapeutics over the last few years. Total assets refers to the total amount of Cidara Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cidara Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Cidara Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 214.8 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Cidara Total Assets Regression Statistics

	Arithmetic Mean	72,494,800
	Geometric Mean	18,175,456
	Coefficient Of Variation	94.49
	Mean Deviation	47,909,525
	Median	68,976,000
	Standard Deviation	68,503,029
	Sample Variance	4692.7T
	Range	225.3M
	R-Value	0.75
	Mean Square Error	2208.6T
	R-Squared	0.56
	Significance	0.0008
	Slope	10,774,409
	Total Sum of Squares	70390T

Cidara Total Assets History

	2025	225.5 M
	2024	214.8 M
	2023	67 M
	2022	47.6 M
	2021	75.3 M
	2020	60.4 M
	2019	69 M

Other Fundumenentals of Cidara Therapeutics

Intangibles To Total Assets

Cidara Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Total Current Assets	Net Tangible Assets	Common Stock	Property Plant Equipment	Capital Surpluse	Net Receivables	Long Term Debt Total	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Current Deferred Revenue	Capital Stock
Total Assets		0.94	-0.98	-0.75	0.65	0.4	0.45	1.0	0.27	-0.06	-0.18	0.5	0.02	-0.59	-0.55	-0.55	0.64	0.67	0.57	-0.33
Total Stockholder Equity	0.94		-0.97	-0.49	0.5	0.24	0.11	0.94	0.37	-0.39	-0.08	0.2	-0.31	-0.34	-0.3	-0.32	0.81	0.82	0.31	-0.6
Net Debt	-0.98	-0.97		0.65	-0.59	-0.35	-0.32	-0.99	-0.34	0.17	0.1	-0.4	0.13	0.49	0.47	0.48	-0.7	-0.73	-0.49	0.41
Retained Earnings	-0.75	-0.49	0.65		-0.61	-0.52	-0.87	-0.74	0.15	-0.48	0.39	-0.91	-0.52	0.89	0.82	0.79	-0.18	-0.26	-0.86	-0.19
Accounts Payable	0.65	0.5	-0.59	-0.61		0.53	0.63	0.65	0.44	0.3	-0.24	0.55	0.51	-0.6	-0.4	-0.37	0.02	0.02	0.53	0.07
Long Term Debt	0.4	0.24	-0.35	-0.52	0.53		0.56	0.39	0.1	0.37	-0.18	0.55	0.32	-0.56	-0.41	-0.37	-0.05	-0.02	0.38	0.16
Total Liab	0.45	0.11	-0.32	-0.87	0.63	0.56		0.43	-0.1	0.81	-0.26	0.94	0.83	-0.81	-0.77	-0.72	-0.28	-0.21	0.84	0.59
Total Current Assets	1.0	0.94	-0.99	-0.74	0.65	0.39	0.43		0.28	-0.08	-0.18	0.49	0.0	-0.58	-0.54	-0.54	0.65	0.68	0.56	-0.35
Net Tangible Assets	0.27	0.37	-0.34	0.15	0.44	0.1	-0.1	0.28		-0.07	0.45	-0.16	-0.18	0.02	0.19	0.21	-0.04	-0.08	-0.31	-0.11
Common Stock	-0.06	-0.39	0.17	-0.48	0.3	0.37	0.81	-0.08	-0.07		0.0	0.69	0.83	-0.51	-0.53	-0.48	-0.74	-0.67	0.47	0.94
Property Plant Equipment	-0.18	-0.08	0.1	0.39	-0.24	-0.18	-0.26	-0.18	0.45	0.0		-0.28	-0.31	0.36	0.17	0.29	-0.17	-0.15	-0.42	0.14
Capital Surpluse	0.5	0.2	-0.4	-0.91	0.55	0.55	0.94	0.49	-0.16	0.69	-0.28		0.66	-0.87	-0.76	-0.71	-0.13	-0.05	0.86	0.44
Net Receivables	0.02	-0.31	0.13	-0.52	0.51	0.32	0.83	0.0	-0.18	0.83	-0.31	0.66		-0.53	-0.43	-0.38	-0.61	-0.58	0.6	0.74
Long Term Debt Total	-0.59	-0.34	0.49	0.89	-0.6	-0.56	-0.81	-0.58	0.02	-0.51	0.36	-0.87	-0.53		0.76	0.7	-0.03	-0.07	-0.67	-0.21
Short Long Term Debt	-0.55	-0.3	0.47	0.82	-0.4	-0.41	-0.77	-0.54	0.19	-0.53	0.17	-0.76	-0.43	0.76		0.97	-0.05	-0.16	-0.73	-0.36
Short Term Debt	-0.55	-0.32	0.48	0.79	-0.37	-0.37	-0.72	-0.54	0.21	-0.48	0.29	-0.71	-0.38	0.7	0.97		-0.1	-0.2	-0.74	-0.33
Net Invested Capital	0.64	0.81	-0.7	-0.18	0.02	-0.05	-0.28	0.65	-0.04	-0.74	-0.17	-0.13	-0.61	-0.03	-0.05	-0.1		0.99	0.11	-0.85
Net Working Capital	0.67	0.82	-0.73	-0.26	0.02	-0.02	-0.21	0.68	-0.08	-0.67	-0.15	-0.05	-0.58	-0.07	-0.16	-0.2	0.99		0.17	-0.79
Current Deferred Revenue	0.57	0.31	-0.49	-0.86	0.53	0.38	0.84	0.56	-0.31	0.47	-0.42	0.86	0.6	-0.67	-0.73	-0.74	0.11	0.17		0.29
Capital Stock	-0.33	-0.6	0.41	-0.19	0.07	0.16	0.59	-0.35	-0.11	0.94	0.14	0.44	0.74	-0.21	-0.36	-0.33	-0.85	-0.79	0.29

Click cells to compare fundamentals

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	214.8 M	225.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC